Kaplan-MachlisBKlostermeyerBS. The cyclooxygenase-2 inhibitors: Safety and effectiveness. Ann Pharmacother1999;33:979–88.
2.
NaranjoCABustoUSellersEMSandorPRuizIRobertsEAA method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981;30:239–45.
3.
WolfeMM. Future trends in the development of safer nonsteroidal anti-inflammatory drugs. Am J Med1998;105(suppl 5A):44S–52S.
4.
Catella-LawsonFMcAdamBMorrisonBWKapoorSKujubuDAntesLEffects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther1999;289:735–41.
5.
RossatJMaillardMNussbergerJBrunnerHBurnierM. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther1999;66:76–84.
6.
BrooksPMDayR. Nonsteroidal antiinflammatory drugs: Differences and similarities. N Engl J Med1991;324:1716–25.
7.
MenePPuglieseFPatronoC. The effects of nonsteroidal antiinflammatory drugs on human hypertensive vascular disease. Semin Nephrol1995;15:244–52.
8.
SpanglerRS. Cyclooxygenase 1 and 2 in rheumatic disease: Implications for nonsteroidal anti-inflammatory drug therapy. Semin Arthritis Rheum1996;26:436–47.
